F3 peptide acetate is a nucleolin-binding tumor-homing peptide that mediates selective uptake and internalization by tumor cells. F3 peptide acetate is a 31-amino acid fragment of human high mobility group nucleosomal protein 2 (HMGN2). F3 peptide acetate inhibits protein synthesis through ribosome inactivation. F3 peptide acetate targets the tumor vasculature. F3 peptide acetate can serve as an effective ligand to improve the druggability of macromolecular drugs or nanoparticles. F3 peptide acetate is used in research on cancers such as glioblastoma and breast cancer [1] [2].
In Vitro, FITC-F3 peptide acetate (10 nM; 2 h) binds to the 231-H2N cell membrane, internalizes, and translocates to the nucleus and nucleolus, colocalizing with nucleolin[2].
References:
[1]. Ham SH, et al. Molecular tumor targeting of gelonin by fusion with F3 peptide. Acta pharmacologica Sinica. 2017 Jun;38(6):897-906.
[2]. Cornelissen B, et al. 111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI research. 2012 Feb 20;2:9.
In Vitro, FITC-F3 peptide acetate (10 nM; 2 h) binds to the 231-H2N cell membrane, internalizes, and translocates to the nucleus and nucleolus, colocalizing with nucleolin[2].
References:
[1]. Ham SH, et al. Molecular tumor targeting of gelonin by fusion with F3 peptide. Acta pharmacologica Sinica. 2017 Jun;38(6):897-906.
[2]. Cornelissen B, et al. 111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI research. 2012 Feb 20;2:9.
















